Shenzhen Weiguang Biological Products Co., Ltd. (SHE:002880)
China · Delayed Price · Currency is CNY 21.10
-0.39 (-1.81%)
Oct 14, 2026, 11:59 AM CST
SHE:002880 Ratios and Metrics
Market cap in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 13, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
| 4,785 | 5,783 | 6,126 | 7,967 | 7,233 | 7,298 | |
Market Cap Growth | -22.05% | -5.59% | -23.11% | 10.16% | -0.90% | -6.20% |
Enterprise Value | 5,570 | 6,423 | 6,434 | 8,271 | 7,256 | 7,063 |
Last Close Price | 21.49 | 25.30 | 26.62 | 34.37 | 31.03 | 31.06 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 13, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
PE Ratio | 26.62 | 23.48 | 24.16 | 36.44 | 61.55 | 35.53 |
Forward PE | 24.99 | 19.07 | 22.23 | 31.51 | 13.16 | 18.82 |
PS Ratio | 4.07 | 4.57 | 5.09 | 7.60 | 10.83 | 8.04 |
PB Ratio | 1.99 | 2.37 | 2.73 | 3.90 | 3.87 | 4.08 |
P/TBV Ratio | 2.17 | 2.58 | 2.98 | 4.29 | 4.14 | 4.36 |
P/FCF Ratio | - | 61.86 | - | 115.33 | - | 1204.41 |
P/OCF Ratio | 44.77 | 21.98 | 34.46 | 20.02 | 6032.03 | 29.56 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 13, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
EV/Sales Ratio | 4.72 | 5.07 | 5.35 | 7.89 | 10.86 | 7.78 |
EV/EBITDA Ratio | 15.02 | 14.53 | 14.59 | 25.20 | 40.17 | 25.15 |
EV/EBIT Ratio | 25.90 | 22.14 | 19.87 | 34.19 | 62.32 | 31.20 |
EV/FCF Ratio | - | 68.70 | - | 119.73 | - | 1165.53 |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 13, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Debt / Equity Ratio | 0.34 | 0.35 | 0.31 | 0.26 | 0.29 | 0.02 |
Debt / EBITDA Ratio | 2.21 | 1.92 | 1.58 | 1.63 | 3.01 | 0.15 |
Debt / FCF Ratio | - | 9.10 | - | 7.77 | - | 7.17 |
Net Debt / Equity Ratio | 0.31 | 0.20 | 0.12 | 0.13 | 0.14 | -0.16 |
Net Debt / EBITDA Ratio | 2.00 | 1.09 | 0.61 | 0.80 | 1.40 | -1.03 |
Net Debt / FCF Ratio | -12.28 | 5.14 | -3.46 | 3.80 | -0.77 | -47.64 |
Asset Turnover | 0.35 | 0.36 | 0.39 | 0.39 | 0.29 | 0.47 |
Inventory Turnover | 0.82 | 0.92 | 0.95 | 0.96 | 0.83 | 1.33 |
Quick Ratio | 0.85 | 1.12 | 1.73 | 1.55 | 2.21 | 3.22 |
Current Ratio | 2.55 | 2.37 | 3.61 | 4.15 | 4.93 | 5.98 |
Return on Equity (ROE) | 7.70% | 10.48% | 11.84% | 11.12% | 6.63% | 12.02% |
Return on Assets (ROA) | 3.93% | 5.15% | 6.55% | 5.55% | 3.18% | 7.37% |
Return on Invested Capital (ROIC) | 5.83% | 9.27% | 11.49% | 9.68% | 5.68% | 14.08% |
Return on Capital Employed (ROCE) | 7.30% | 9.60% | 11.30% | 9.30% | 5.00% | 12.30% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 13, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Earnings Yield | 3.76% | 4.26% | 4.14% | 2.74% | 1.63% | 2.81% |
FCF Yield | -1.26% | 1.62% | -1.27% | 0.87% | -4.51% | 0.08% |
Dividend Yield | 0.95% | 0.79% | 0.75% | 1.16% | - | 0.64% |
Payout Ratio | 59.09% | 26.68% | 25.99% | 30.00% | 49.09% | 20.36% |
Buyback Yield / Dilution | 0.01% | 0.00% | -0.00% | -0.01% | 0.01% | -0.00% |
Total Shareholder Return | 0.94% | 0.79% | 0.75% | 1.16% | 0.01% | 0.64% |